Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director departure
Appointed director
CC transcript
Upcoming conference date
Auditor change
Appointed CFO
PONIARD PHARMACEUTICALS, INC. (PARD) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/02/2012 8-K Quarterly results
01/05/2012 8-K Form 8-K - Current report
12/23/2011 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Merger Termination Agreement between Poniard Pharmaceuticals, Inc. and Allozyne, Inc.",
"Poniard Pharmaceuticals and Allozyne Terminate Planned Merger"
11/22/2011 8-K Form 8-K - Current report
11/02/2011 8-K Form 8-K - Current report
09/07/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares"
08/16/2011 8-K Form 8-K - Current report
07/12/2011 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Poniard Pharmaceuticals Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal Reverse Stock Split Necessary to Maintain Listing on Nasdaq Capital Market, Required for Proposed Merger with ALLOZYNE; Meeting to Reconvene on July 22, 2011 to Consider Reverse Stock Split Proposal"
06/27/2011 8-K Form 8-K - Current report
04/18/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Poniard Pharmaceuticals Announces it Will Seek Shareholder Approval of Reverse Stock Split at Annual Meeting"
03/30/2011 8-K Quarterly results
Docs: "Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results"
03/02/2011 8-K Form 8-K - Current report
02/24/2011 8-K Form 8-K - Current report
02/08/2011 8-K Form 8-K - Current report
01/24/2011 8-K Form 8-K - Current report
12/21/2010 8-K Form 8-K - Current report
12/16/2010 8-K Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation o...
Docs: "Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan"
12/01/2010 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Lease Agreement dated November 24, 2010, between Selig Holdings Company and Poniard Pharmaceuticals, Inc"
11/09/2010 8-K Quarterly results
Docs: "Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results"
09/14/2010 8-K Form 8-K - Current report
07/23/2010 8-K Form 8-K - Current report
06/14/2010 8-K Form 8-K - Current report
06/08/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer"
05/10/2010 8-K Quarterly results
Docs: "Poniard Pharmaceuticals Reports First Quarter 2010 Financial Results - Conference Call Today at 4:30 p.m. Eastern Time -"
03/25/2010 8-K Form 8-K - Current report
03/19/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter"
03/12/2010 8-K Form 8-K - Current report
03/08/2010 8-K Form 8-K - Current report
02/23/2010 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Common Stock Purchase Agreement, by and between Poniard Pharmaceuticals, Inc. and Commerce Court Small Cap Value Fund, Ltd",
"Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility"
02/19/2010 8-K Form 8-K - Current report
02/11/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1, to Amended and Restated Change of Control Agreement, between the Company and Ronald A. Martell",
"Amendment No. 1, to Amended and Restated Key Executive Severance Agreement, between the Company and Ronald A. Martell",
"Change of Control Agreement, between the Company and Michael S. Perry, DVM, PhD",
"Key Executive Severance Agreement, between the Company and Michael S. Perry, DVM, PhD",
"Consulting Agreement, between the Company and Robert De Jager, M.D"
02/03/2010 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Poniard Pharmaceuticals Announces Management Changes and Reduction in Force"
01/27/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives Statistical data support picoplatin as a potential neuropathy-sparing alternative to oxaliplatin"
12/24/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Poniard Pharmaceuticals Announces $6.5 Million Financing"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy